The FDA has updated the label for Ozempic (the generic form is Semaglutide) to include the potential risk for ileus (intestinal blockage). While this condition can resolve on its own, it can in some case become serious and life-threatening. Another new condition on the label is an increased risk for hypoglycemia (very low blood sugar) if used in combination with insulin or an insulin secretagogue like sulfonylurea.
If you were taking Semaglutide for weight management, you should discuss these potential side effects with your prescriber and discuss what symptoms to watch out for and when to stop the medication.

#OzempicUpdate
#SemaglutideLabel
#MedicalNews
#IleusRisk
#HypoglycemiaWarning
#MedicationSafety
#HealthAwareness
#FDAAlert
#WeightManagement
#PrescriptionMeds
#PatientSafety
#DiscussWithDoctor
#SideEffects
#HealthInformation
#MedicationReview

свернуть